Cargando…

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Van Dijkhuizen, EH Pieter, Bulatović, Maja, Heijstek, Marloes W, Wulffraat, Nico M, Pluijm, Saskia MF, de Jonge, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194453/ http://dx.doi.org/10.1186/1546-0096-9-S1-P105

Ejemplares similares

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

PReS-FINAL-2162: Development of a risk model to predict methotrexate intolerance in juvenile idiopathic arthritis
por: Van Dijkhuizen, P, et al.
Publicado: (2013)

Prediction of Methotrexate Intolerance in Juvenile Idiopathic Arthritis: a prospective, observational cohort study
por: van Dijkhuizen, Evert Hendrik Pieter, et al.
Publicado: (2015)

Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: van Dijkhuizen, EH Pieter, et al.
Publicado: (2014)

Early predictors of prognosis in juvenile idiopathic arthritis patients: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Experience of the concentration of methotrexate evaluation in children with juvenile idiopathic arthritis
por: Rokhlina, FV, et al.
Publicado: (2011)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Methotrexate does not primarily affect Foxp3+ regulatory T cells in poly-articular juvenile idiopathic arthritis
por: Vastert, SJ, et al.
Publicado: (2008)

Reasons for stopping methotrexate treatment in patients with juvenile idiopathic arthritis
por: Carolina Da Silva, Ana, et al.
Publicado: (2014)

Efficacy of oral versus subcutaneous methotrexate in children with juvenile idiopathic arthritis
por: Tzaribachev, N, et al.
Publicado: (2008)

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis
por: Albers, HM, et al.
Publicado: (2008)

Genetic determinants of methotrexate treatment efficacy in patients with juvenile idiopathic arthritis
por: Avramovič, Mojca Zajc, et al.
Publicado: (2014)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Validation of the juvenile artritis disease activity score in 1124 patient visits
por: de Vries, LD, et al.
Publicado: (2011)

A three minute- screening tool for temporomandibular joint involvement in children with juvenile idiopathic arthritis
por: Giancane, Gabriella, et al.
Publicado: (2014)

PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis
por: Pastore, S, et al.
Publicado: (2013)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis
por: de Rotte, Maurits C. F. J., et al.
Publicado: (2018)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries
por: Swart, Joost, et al.
Publicado: (2014)

PReS-FINAL-2155: Genetic variability of methotrexate transporters in patients with juvenile idiopathic arthritis
por: Zajc Avramovič, M, et al.
Publicado: (2013)

A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis
por: Bracciolini, GP, et al.
Publicado: (2014)

Genome-Wide Data reveals Novel Genes for Methotrexate Response in a Large Cohort of Juvenile Idiopathic Arthritis Cases
por: Cobb, Joanna, et al.
Publicado: (2014)

Share – Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis
por: Vastert, Sebastiaan, et al.
Publicado: (2014)

Phenotypes of juvenile idiopathic arthritis
por: Rokhlina, Faina, et al.
Publicado: (2014)

Ankle arthritis predicts worse outcome in children with juvenile idiopathic arthritis
por: Esbjörnsson, Anna-Clara, et al.
Publicado: (2014)

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro
por: Wienke, J, et al.
Publicado: (2014)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
por: Bulatović Ćalasan, Maja, et al.
Publicado: (2013)

PReS-FINAL-2095: Older age predicts poor response to 6-months methotrexate therapy in a juvenile idiopathic arthritis cohort of patients
por: Marques, R, et al.
Publicado: (2013)

MTHFR polymorphism and red cell folate levels are not useful as biomarkers of methotrexate efficacy and toxicity in children with juvenile idiopathic arthritis
por: Tuková, J, et al.
Publicado: (2008)

Influence of Reduced Folate Carrier and Aminoimidazole Carboxamide Ribonucleotide Transformylase gene polymorphisms on the efficacy of methotrexate in juvenile idiopathic arthritis
por: Bilginer, Yelda, et al.
Publicado: (2011)

The TLR4 ligands MRP8 and MRP14 in the diagnosis and pathogenesis of systemic onset juvenile idiopathic arthritis
por: Frosch, M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_h2o8oecscqa9liab49mvaopboc